In little over a month, Oxford BioDynamics have inked two deals relating to the distribution and sales of its market leading Prostate Cancer PSE test. Does this mark the start of a turnaround for the company?HTTPS://smallcappix.com/blogdetail?id=77 |
 13 March 2025
Oxford BioDynamics
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Bupa UK insurance to cover Oxford BioDynamics' EpiSwitch® PSE prostate cancer test
· Bupa UK insurance customers with a raised PSA level and no additional high risk factors or symptoms will now be covered for PSE, a smart blood test which accurately predicts the presence or absence of prostate cancer
· Expansion of OBD/Bupa UK insurance partnership beyond existing coverage of CiRT significantly enhances access to PSE in the UK
· Coverage for both OBD's PSE and CiRT3 tests reflects Bupa's commitment to leveraging advanced precision medicine testing to transform cancer care
Oxford, UK - 13 March 2025 - Oxford BioDynamics Plc (AIM: OBD), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, and Bupa announce an expanded strategic agreement to give its health insurance customers access to OBD's EpiSwitch PSE prostate cancer detection test. Bupa is a leading health insurer in the UK with around 3.9m customers.
Robin Clark, Medical Director for Bupa Insurance, said: "We're pleased to partner with Oxford BioDynamics to cover the advanced EpiSwitch PSE test. The PSE provides a more accurate path to diagnosing prostate cancer, where getting an early diagnosis can make the disease nearly completely survivable. Offering the PSE and CiRT tests reflects our commitment to leverage the most advanced precision medicine testing to provide doctors with the tools they need to make informed decisions."
Under this new agreement, the PSE test will be funded for Bupa health insurance customers with a raised prostate-specific antigen level and no additional high-risk factors or urinary symptoms.
The EpiSwitch PSE is OBD's validated, rapid, highly accurate blood test for prostate cancer (accuracy 94%, specificity 97%, sensitivity 86%)1, significantly boosting the accuracy of PSA alone. Crucially, the positive predictive value (PPV) of PSE is 93%, compared to just 25% for PSA. PSA's low PPV is one of the main arguments against using it as a population-wide screening test. About 25% of men with a raised PSA will go on to be diagnosed with prostate cancer. With the PSE, more than 9 out of every 10 men who receive a positive "high likelihood" PSE will go on to have a confirmatory biopsy1. This level of performance can reduce the total number of men who do not have prostate cancer being referred for unnecessary MRI scans and invasive biopsies2. These clinical results are supported by an accumulation of real-world evidence related to the clinical utility.
Iain Ross, Executive Chairman of OBD, said: "Joining forces with a pioneering healthcare insurer like Bupa ensures that more men have access to an accurate diagnosis by using the EpiSwitch PSE test. Prostate Cancer is the most common cancer in men in the UK, and yet there is currently no nationwide screening programme due to limitations of current testing modalities. With its high accuracy and PPV, EpiSwitch PSE can be integrated into existing pathways to more precisely direct individuals toward further expensive and invasive diagnostics and treatments. We remain focused on forging strategic partnerships to build on this momentum and continue to drive value." |
www.bbc.com/news/articles/cgl00gn15y8o.amp
OBD sat on a goldmine!
Serious questions being asked by leaders in the field with regards to PSA tests, OBD tests are superior and they are desperately needed. Prostate cancer is the fastest growing cancer worldwide.
When this takes off, there will be no stopping.
DYOR |
Setting the bar very low with those options . One of my other companies set their target price at 5x the current share price and has had directors buying in the open market . Says a lot about how optimistic they are here . |
Good to know thanks |
There won't be another placing until March 2026. Meanwhile, there could be some exciting news on the commercial side. Sit tight. |
RNS details (Note 2, Going Concern):
'The Board considers that the Upside Forecast represents a reasonable estimate of the Group's potential performance over the period to 31 March 2026.
..with income reflected in the Upside Forecast, cash resources would be expected to last beyond 31 March 2026.' |
Yup it is . Just remember anyone buying now you were warned 0.2p placing imo |
Next fund raise will be 0.2p probably no point until then this is a disaster until they can raise money and slash coats . Even then it's going to take an awful lot of good news and increased sales to get anywhere near |
So much for predictions. The proof is in the numbers. This is going to tank back to 40s again |
Zak Mir predicts that the share price will go up to 0.9 / 1 p level. |
Those figures look even worse to me they are still burning through cash and don't have much left at all . Poorly managed and why the share price continues to fall and likely will again today . The tech is good but just another example of poor British management not keeping control and ensuring enough funding is in place to reach then end game of sales and income .
I would say they have got the timing wrong by about 2 years here . Revenues not increasing anywhere near fast enough and losses increasing really bad.
Several times he slides to more fund raises being required and streamlining the business with the help of shareholders . I suspect a lot more pain to come here with more rights issues at lower prices. Until they reach a point they can sustain the business or it goes under
A shame the new guy didn't arrive much sooner he seems to have the right idea but unfortunately it may be to late . He will have to raise money the hard way and in these markets that will be painful . If he can do it though the longer term they might survive and do well but it's a long way off and a lot of pain before it gets there |
18 June results the company lost £6 million for the year, that's a bonkers amount of money to waste, hopefully tomorrow figures will be vastly improved. |
Market looks forward not back,the results should be very positive as far as the future is concerned,the past has gone,OBD going to grow into a fantastic company,this is one of the very few AIM companies which are worth a long term investment and not a five minute trade. |
The results imo will not likely amaze but that's not the investment thesis here right now - it's about the turnaround and Iain getting the partners Rishi sunak at the OBD labs is interesting given the company are now engaged with the nhs |
Let's gear up for the result tomorrow. I expect a positive reaction. |
https://zakstraderscafe.com/weekend-bulletin-board-heroes-february-23/10883/Zak covers it on his weekend coverage suggesting 0.91 initially It's at 8mins and 41 seconds for those interested. |
The way that the chart is behaving you can see it for yourself that it can shoot up to 2 p on a very positive RNS. I do expect some good news flow in the coming months. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
